---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-025663"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:22:22.873724+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pliant assembles outside expert panel to review bexotegrast trial after DSMB pause recommendation

## Summary
- DSMB recommended pause of enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast in IPF.
- Company initiated assembly of outside expert panel (pulmonary experts and biostatisticians) to review unblinded data.
- Company could not determine DSMB rationale from blinded data; panel will provide independent recommendation then join expanded DSMB.
- Process expected to conclude in 2-4 weeks; company remains blinded to maintain trial's potential as registrational.

## SEC filing metadata
- accession: 0001193125-25-025663
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312525025663/0001193125-25-025663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312525025663/d892128d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-025663
- JSON: https://secwatch.observer/filing/0001193125-25-025663.json
- Plain text: https://secwatch.observer/filing/0001193125-25-025663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.